- Home
- CBNA vs CYBN Comparison
CBNA vs CYBN Comparison
Compare CBNA & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- CYBN
- Stock Information
- Founded
- CBNA 2006
- CYBN 2019
- Country
- CBNA United States
- CYBN Canada
- Employees
- CBNA N/A
- CYBN N/A
- Industry
- CBNA
- CYBN Pharmaceuticals and Biotechnology
- Sector
- CBNA
- CYBN Health Care
- Exchange
- CBNA NYSE
- CYBN Nasdaq
- Market Cap
- CBNA 159.8M
- CYBN 153.7M
- IPO Year
- CBNA 2024
- CYBN N/A
- Fundamental
- Price
- CBNA $24.00
- CYBN $6.35
- Analyst Decision
- CBNA Buy
- CYBN Strong Buy
- Analyst Count
- CBNA 3
- CYBN 4
- Target Price
- CBNA $29.67
- CYBN $86.00
- AVG Volume (30 Days)
- CBNA 10.1K
- CYBN 157.8K
- Earning Date
- CBNA 05-15-2025
- CYBN 02-11-2025
- Dividend Yield
- CBNA N/A
- CYBN N/A
- EPS Growth
- CBNA 115.79
- CYBN N/A
- EPS
- CBNA 4.17
- CYBN N/A
- Revenue
- CBNA $53,113,000.00
- CYBN N/A
- Revenue This Year
- CBNA N/A
- CYBN N/A
- Revenue Next Year
- CBNA $28.23
- CYBN N/A
- P/E Ratio
- CBNA $5.82
- CYBN N/A
- Revenue Growth
- CBNA 74.81
- CYBN N/A
- 52 Week Low
- CBNA $20.10
- CYBN $6.20
- 52 Week High
- CBNA $27.56
- CYBN $17.86
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- CYBN 24.83
- Support Level
- CBNA N/A
- CYBN $7.16
- Resistance Level
- CBNA N/A
- CYBN $7.09
- Average True Range (ATR)
- CBNA 0.00
- CYBN 0.33
- MACD
- CBNA 0.00
- CYBN -0.03
- Stochastic Oscillator
- CBNA 0.00
- CYBN 9.93
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.